P
ulmonary arterial hypertension (PAH) is a vascular disease in which pulmonary vascular obstruction, caused by vasoconstriction, inflammation, fibrosis, and a proliferation/apoptosis imbalance, increases right ventricular afterload, leading to fatal right ventricular failure. 1 Excessive cell proliferation and apoptosis resistance are important features of pulmonary artery smooth muscle cells (PASMCs) in both patients with PAH and rodent models of PAH. This "neoplastic phenotype" of PAH PASMCs persists in cell culture and is promoted by acquired changes in mitochondrial metabolism, including a shift to uncoupled glycolysis, known as the Warburg phenomenon, 2 and fragmentation of the mitochondrial network. 3 Mitochondria exist in dynamic networks that undergo continuous fission (division) and fusion (union). 4 Altered mitochondrial dynamics in PAH result, in part, from excessive mitochondrial fission caused by increased activation of the fission-mediating GTPase dynamin-related protein 1 (Drp1). 3, 5, 6 When activated, Drp1 moves from the cytosol to the outer mitochondrial membrane, where it interacts with its binding partners in a multimerization reaction that culminates in fission. [7] [8] [9] Coordination between mitosis and mitochondrial division ensures equitable distribution of mitochondria between daughter cells and is mediated, in part, by a shared dependence of both processes on similar kinases, including cyclin B-CDK1 (reviewed elsewhere 4 ). Pathological levels of Drp1 activation in both PAH and non-small cell lung cancer, the prototypic disease in which proliferation is increased and apoptosis is suppressed, cause mitochondrial fragmentation and promote an imbalance of proliferation and apoptosis in both conditions. 10 Molecular or chemical inhibition of Drp1 regresses both diseases by causing cell cycle arrest. 3, 10 In mammals, 4 outer mitochondrial membrane proteins act as Drp1 receptors: fission 1 (Fis1), mitochondrial fission factor, and mitochondrial dynamics protein of 49 kDa (MiD49) and 51 kDa (MiD51).
11 MiD49 and MiD51 are expressed on the outer mitochondrial membrane 12 ; however, they also exist in the cytosol, where their role is unknown. 13 Even the role of MiDs as promoters versus inhibitors of fission remains controversial, and their role in human disease is unknown. Overexpression of either MiD49 or MiD51 increases Drp1 recruitment to the mitochondria. 12 In 1 report, MiD overexpression caused fusion, 13 perhaps by acting as bait for Drp1; however, in another study, overexpression enhanced fission, 14 perhaps by enhancing the compactness and efficiency of the fission apparatus. 12 The possibility that MiD49 and MiD51 might have a role in disease has not been assessed, although a recent report identified a single nucleotide polymorphism in MiD49 that was associated with adverse remodeling of small pulmonary arteries in PAH. 15 Moreover, the role of endogenous MiDs in normal cell biology or in human disease is largely unknown, with the few studies to date relying largely on heterologous overexpression of MiDs in cell lines.
Here, we examine the fundamental role of these newly discovered Drp1 binding partners in regulating mitochondrial dynamics and the cell cycle in normal PASMCs and describe the pathological cause and consequences of their dysregulation in PAH. We report that the expression of both MiD49 and MiD51 is pathologically elevated in PASMCs and small pulmonary arteries from patients with PAH, as well as in 2 rodent models of disease. Superresolution confocal imaging reveals the formation of a ring-shaped macromolecular fission apparatus, made up of MiDs and Drp1, at the site of fission. Silencing MiD expression restores mitochon-
Clinical Perspective
What Is New?
• We identify a key role for mitochondrial dynamics protein of 49 and 51 kDa (MiD49 and MiD51), 2 novel mitochondrial binding partners for dynamin-related protein 1, in pulmonary arterial hypertension (PAH).
• Pathological elevation of MiDs in pulmonary artery smooth muscle cells and endothelial cells from human and experimental PAH accelerates mitotic fission and supports rapid cell proliferation.
• MiD expression is epigenetically upregulated by decreased expression of microRNA-34a-3p (miR-34a-3p).
• MiDs cause fission in a dynamin-related protein 1-dependent manner. Silencing MiDs in PAH increases mitochondrial fusion; conversely, overexpressing MiDs in normal cells causes fission.
• Silencing MiDs causes cell cycle arrest (through an extracellular signal-regulated kinases 1/2-and cyclin-dependent kinase 4-dependent mechanism), decreases cell proliferation rate, and increases apoptosis.
What Are the Clinical Implications?
• We identify a decrease of miR-34a-3p expression in the preclinical models of PAH and reduced circulatory miR-34a-3p expression in patient cohorts; miR-34a-3p may be a biomarker of PAH.
• MiDs are similarly dysregulated in PAH blood outgrowth endothelial cells.
• We translated our cellular discoveries into 2 new therapies that regress PAH. In experimental models, nebulizing miR-34a-3p or small interfering RNA against MiD49 or MiD51 regresses pulmonary hypertension.
• The epigenetic acceleration of mitotic fission through the miR-34a-3p-MiD axis promotes the cancer-like deep phenotype of PAH and is a novel therapeutic target. • This study further implicates dysregulation of mitochondrial dynamics as a therapeutic target in human and experimental PAH. 19 These miRs influence disease processes in a variety of tissues, including the right ventricle, skeletal muscle, and pulmonary vasculature. In our study, we demonstrate that MiD expression is epigenetically upregulated by a decrease in miR-34a-3p in both patients with PAH and animal models. Overexpression of either MiD recapitulates the PAH phenotype in normal PASMCs. In contrast, silencing MiD49 or MiD51 or augmenting an miR-34a-3p mimic reverses established PAH in vivo, highlighting the contribution of the miR-34a-3p-MiD-Drp1 axis to the pathophysiology of human and experimental PAH and the viability of this pathway as a target for new therapeutic strategies.
METHODS
The data and analytical methods will be made available to other researchers from the corresponding author on reasonable request for purposes of reproducing the results or replicating the procedure. However, we cannot make the materials available because of their scarcity (in the case of cells and tissues) or cost (in the case of therapeutic siRNAs and miRs).
Cell Culture and Reagents
PAH PASMCs were isolated from patients with PAH. Normal PASMCs were isolated from control subjects or purchased from Lonza (Rochester, NY) or Cell Applications Inc (San Diego, CA). PASMC lines were studied within 6 passages. PASMCs were grown in medium 231 supplemented with smooth muscle growth supplement (Life Technologies, Carlsbad, CA). Experiments were performed on 6 normal PASMC lines (50% female; mean age, 50.7 years) and 8 PAH PASMC lines (28% female; mean age: 41.2 years). Blood outgrowth endothelial cells (BOECs) were isolated and cultured from patients with PAH and healthy individuals (demographics are given in Table I in the online-only Data Supplement) as previously described. 20 Briefly, blood was collected from healthy individuals (n=5) and patients with PAH (n=6) by venipuncture. Peripheral blood mononuclear cells were isolated from the whole blood by density gradient centrifugation. Peripheral blood mononuclear cells were cultured in BOEC generation medium for 7 to 14 days for the appearance of outgrowth colonies.
Immunohistochemistry
To assess localization and expression of MiDs in human (normal, n=6; PAH, n=6; 
Immunofluorescence Staining
Immunofluorescence staining of the formalin-fixed paraffinembedded rat lung tissues was performed as previously described. 21 Briefly, rat lung sections were labeled with smooth muscle actin (Abcam, Cambridge, MA), and von Willebrand factor (Dako Denmark A/S, Glostrup, Denmark) antibodies. Nuclei were labeled with 4', 6-diamidino-2-phenylindole (DAPI) (Life Technologies).
Small Interfering RNA Treatment of PASMCs
For small interfering RNA (siRNA) treatment, PAH PASMCs were grown to 60% to 80% confluence and then transfected with 25 pmol of siRNA using the Lipofectamine RNAiMAX Transfection Reagent (Life Technologies). The sequences of siRNA duplexes specific for human MiD49, MiD51, Fis1, mitochondrial fission factor, rat MiD49, MiD51, and negative control are available in the onlineonly Data Supplement. The knockdown efficiency was assessed after 48 hours with quantitative reverse transcription-polymerase chain reaction (Bio-Rad, Hercules, CA) and 72 hours with immunoblotting.
Cell Cycle Analysis
To assess the effects of MiD expression on cell cycle progression, flow cytometry was performed on cells that were initially synchronized by serum starvation. PAH PASMCs were transfected with siRNA targeting MiD49 or MiD51 versus a control siRNA for 24 hours. After siRNA transfection, the cells were serum-starved for 48 hours to synchronize the cells at G1/G0 phase. The cells were then stimulated with 20% fetal bovine serum/medium 231 for 24 hours. Cells were harvested, suspended in PBS, and fixed with 70% ethanol (vol/vol) at −20°C. The fixed cells were washed twice with cold PBS and incubated with PI/RNase Staining Buffer (BD Biosciences, Franklin Lakes, NJ) at room temperature for 15 minutes. The samples were analyzed through flow cytometry with a fluorescenceactivated cell sorter (Beckman Coulter Inc, Brea, CA).
Cell Proliferation Assay
Cell proliferation was quantified with the Click-iT EdU kit according to the manufacturer's instructions (Life Technologies). Measurements were made 72 hours after administration of siRNA or plasmid transfection.
Apoptosis Assay
Cells were grown in 100-mm dishes and were harvested and counted at 80% to 90% confluence. Then, 1.5×10 6 cells were electroporated (LONZA 4D-Nucleofector, . Continuous mitochondrial structures were counted with the ImageJ particle-counting subroutine, and the number was normalized to the total mitochondrial area to obtain the mitochondrial fragmentation count for each image, a previously validated measure of mitochondrial fragmentation. 10 For every intervention, 8 to 25 randomly selected cells were imaged by a blinded microscopist, and the mitochondrial fragmentation count was calculated. A lower mitochondrial fragmentation count indicates a more fused mitochondrial network.
Machine Learning
Mitochondrial morphology was further analyzed by a machine-learning-based categorization with the Leica LAS X software. Briefly, all mitochondria in each cell were divided into 3 categories (punctate, intermediate, or filamentous) based on their morphology. Fifteen to 20 mitochondria from each group were manually identified and categorized to inform the machine-learning algorithm. The algorithm is calculated on the basis on the characteristics (area, length, and sphericity) of the mitochondria. Then the algorithm was applied to all the images. The percentage area of each category in each confocal image was calculated, and the distribution of the 3 categories was compared among groups.
Mitochondrial Networking
Mitochondrial networking was determined with mitochondria-targeted, photo-activatable green fluorescent protein by a metric called the mitochondrial networking factor. An increase in mitochondrial networking factor indicates a higher degree of mitochondrial network fusion. 3, 10 Whole-Cell Micropolarimetry PASMC micropolarimetry was performed by mitochondrial flux measured with Seahorse XFe24 (Seahorse Biosciences, North Billerica, MA) in PAH PASMCs after 48 hours of transfection with siMiD49 or siMiD51. Details of the methodology are described in the online-only Data Supplement.
MicroRNA Microarray
To identify candidate miRs that are dysregulated in PAH, we performed an miR microarray study. Total RNA from cultured PASMCs of 6 patients with PAH and 3 healthy subjects was extracted with the mirVana microRNA (miRNA) isolation kit (Ambion/Life Technologies). RNA quality was assessed by measurement of absorbance at 260 and 280 with a spectrophotometer (cutoff, 1.8-2.2) and by calculation of an RNA integrity number in an Agilent Bioanalyzer (RNA integrity number >6). Microarray experiments were carried out at the Center for Applied Genomics at the Hospital for Sick Children (Toronto, Canada). Differential expression of miRNAs between the PAH and control cohorts was examined with the Affymetrix GeneChip miRNA 4.0 Array (Affymetrix, Santa Clara, CA). RNA samples were prepared with the FlashTag Biotin HSR RNA Labeling Kit (Affymetrix) before hybridization at 48°C for 16 to 18 hours. Fluorescent signals were captured with the Affymetrix GeneChip Scanner 3000. Affymetrix CEL files were normalized with the robust multiarray average algorithm within the Affymetrix Expression Console Software (version 1.4.1.46). The resulting normalized files were then analyzed within the transcriptome analysis console (version 3.1.0.5), and a 1-way between-subjects ANOVA (unpaired) was applied. These final data were then filtered to include only human miRs that satisfied a 2-fold cutoff and P<0.05.
All data have been submitted to the National Center for Biotechnology InformationGene Expression Omnibus (GEO accession number, GSE108707).
In Silico Analysis of miRNAs Binding to MiD49 and MiD51
To identify which miRNAs can bind to MiD49 and MiD51, in silico analysis using Target Scan 7.0 and miRDB (http://www. mirdb.org) were used. Of the 25 downregulated miRNAs, we identified miR-34a-3p as the only predicted regulator of MiD51. Although none of the downregulated miRNAs were predicted to regulate MiD49, analysis using nucleotide basic local alignment search tool identified potential miR-34a-3p target sites within the 3′ untranslated region (UTR) of MiD49 and MiD51. 3′-UTR sequences of MiD49 and MiD51 were obtained from the University of California, Santa Cruz Gene Sorter (http://genome.ucsc.edu/). The nucleotide sequence of hsa-miR-34a-3p (accession number, MIMAT0004557) was extracted from miRBase release 21 (http://www.mirbase.org). 
Animal Studies
All protocols were approved by the Queen's University and Laval University Animal Care Committees.
Monocrotaline PAH Model
The monocrotaline-induced PAH model in rats was created by subcutaneous injection of 60 mg/kg monocrotaline, as previously described. 21 PAH was allowed to develop for 7 days before intervention. Experiments were performed 3 weeks after monocrotaline injection. Randomization and blinding were included in the study design for the duration of the protocol, including analysis.
Su/Hx PAH Model
This model was created as previously described. 22 Experiments were performed 3 weeks after removal from the hypoxic chamber.
siMiD49, siMiD51, or miR-34a-3p Mimic Therapy
Briefly, 1 nmol siMiD49 or siMiD51 or control siRNA and 5 nmol miR-34a-3p or miR-control were administered 1 week after monocrotaline injection to the anesthetized rat by nebulization in 50 μL saline with an aerosol nebulizer (AG-AL7000STD, Kent Scientific, Torrington, CT). siRNAs were procured from Integrated DNA Technology (Coralville, IA). miR-34a-3p and miR-control were purchased from Life Technologies. Both the siRNAs against MiDs and the control siRNA were modified for a higher stability for in vivo studies.
Hemodynamics
Mean pulmonary artery pressure, right ventricular systolic pressure, and cardiac output were measured with closedchest technique under anesthesia with 2.5% isoflurane (enriched O 2 1.5 mL/min), as previously described. 21 
Statistical Analyses
Quantitative data are presented as mean±SEM. Intergroup differences were assessed with the Student t test (unpaired or paired) or 1-way ANOVA as appropriate. For in vivo studies, the Šídák multiple-comparisons test was used to determine statistical significance of multiple comparisons. Statistical analyses were performed with the GraphPad Prism 7.0d software package. A value of P<0.05 was considered statistically significant. Table I in the onlineonly Data Supplement) from patients with PAH. Confocal microscopy of PAH PASMCs localized some of this increased expression to the mitochondria. Stimulated emission depletion superresolution microscopy, which has a resolution 5 times greater than confocal microscopy (50 nm), revealed MiDs within the macromolecular fission apparatus at the constriction point of the mitochondria, adjacent to Drp1 ( Figure 1B) . The ring-shaped macromolecular fission apparatus is found at points of fission in normal and PAH PASMC mitochondria. In PAH, we observed more MiDs at the focal area of fission and noted that the fission apparatus appeared "tighter" (ie, more dense) than in normal PASMCs. However, endogenous MiDs are also found in the cytosol, as previously observed. 13 Immunohistochemistry of lungs from patients with PAH ( Figure IC and Table I in the onlineonly Data Supplement) and rats with monocrotalineand Su/Hx-induced PAH ( Figure 1D and Figure IC in the online-only Data Supplement) confirmed the increased expression of MiD49 and MiD51 in the media (PASMCs) and intima (pulmonary artery endothelial cells) of diseased pulmonary arterioles. 
RESULTS

Increased Expression of MiD49 or MiD51 in PAH
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Silencing MiD49 or MiD51 Promotes Mitochondrial Fusion
As reported previously, 3 PAH PASMCs exhibit a fragmented mitochondrial network, which was also observed in PAH BOECs ( Figure ID and IE in the onlineonly Data Supplement). Resonant scanning showed that effective knockdown of either MiD ( Figure IIA and IIB in the online-only Data Supplement) led to increased mitochondrial motion (Movies I-III in the online-only Data Supplement). Knocking down MiDs also inhibited mitochondrial fission (Figure 2A ) (reduced mitochondrial fragmentation count) 10 and increased the percentage area of filamentous mitochondria (measured by machine learning; Figure 2B ). Furthermore, silencing MiDs increased mitochondrial fusion, evident as an increase in the mitochondrial networking factor. Increased mitochondrial networking factor reflects a more rapid diffusion of photoactivated green fluorescent protein within the mitochondrial matrix ( Figure 2C and 2D) . Overexpression of either MiD in PASMCs from control subjects led to mitochondrial fission, creating a phenotype similar to that seen in PAH PASMCs ( Figure 2E and 2F) . However, MiD overexpression failed to cause mitochondrial fragmentation in Drp1 knockout mouse embryonic fibroblasts ( Figure IIIA 25 Knockdown of MiD49 or MiD51 in PAH PASMCs reduced the Drp1 serine 616 phosphorylation ( Figure 3A and Figure IXA in the online-only Data Supplement) and decreased ERK1/2 phosphorylation in PAH PASMCs stimulated with platelet-derived growth factor (PDGF; Figure 3B and Figure IXB in the online-only Data Supplement). Moreover, silencing MiDs downregulated the expression of the PDGF receptors α and β ( Figure 3C ) and inhibited Raf-1 phosphorylation ( Figure IXC in the online-only Data Supplement), suggesting that silencing MiDs inhibits mitochondrial fission and cell proliferation, in part, by inhibition of the PDGF-Raf-1-ERK1/2 signaling pathway.
Silencing MiDs repressed the expression and activity of cyclin-dependent kinase 4 (CDK4) by inhibiting its phosphorylation at threonine 172 ( Figure 3D , and (F) p27 Kip1 . Pulmonary arterial hypertension pulmonary artery smooth muscle cells were transfected with siMiD49 or siMiD51. Cells were harvested for immunoblot analyses after 48 hours of transfection. β-Actin was used as the loading control (*P<0.05, **P<0.01, ***P<0.001; n=3-4 per group). Ctrl indicates control; siMiD, small interfering RNA against MiD49 or MiD51; and siRNA, small interfering RNA.
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Figure 4. MicroRNA (miR)-34a-3p is decreased in pulmonary arterial hypertension (PAH) and is a negative regulator of mitochondrial dynamics protein of 49 and 51 kDa (MiD49 and MiD51).
A, miRNA expression profiling in PAH and normal pulmonary artery smooth muscle cells (PASMCs). Volcano plot showing expression change of miRNAs in PAH relative to control samples. Each dot represents 1 probe set. Red indicates reduction; green, increase; n=3 for normal PASMCs and n=6 for PAH PASMCs. B, In silico prediction of miR-34a-3p targeting MiD49 and MiD51. i, The putative binding site of miR-34a-3p on the 3′ untranslated region (UTR) of MiD49 as predicted by nucleotide BLAST. ii, Nucleotide sequences of MiD49 3′-UTR and miR-34a-3p. The predicted binding site is highlighted in red. Nucleotide positions are indicated in parentheses. iii, The 2 putative binding sites of miR-34a-3p on the 3′-UTR of MiD51. iv, Nucleotide sequences of MiD51 3′-UTR and miR-34a-3p. Predicted target sites are highlighted in blue. Nucleotide positions are indicated in parentheses. The expected value is calculated by BLAST to describe the number of hits one can "expect" to see by chance. The lower the expect value is, the more significant the match is. C, miR-34a-3p is decreased in PAH PASMCs. Quantification of miR34a-3p was performed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) (**P<0.01; n=4 for normal PASMCs and n=6 for PAH PASMCs). D, miR-34a-3p binds to 3′-UTRs of MiD49 and MiD51. miR-34a-3p was found to repress the activity of luciferase reporter, indicating its binding to the 3′-UTRs of MiD49 and MiD51 genes (**P<0.01; n=5 and 8 for MiD49 and MiD51, respectively). E, miR-34a-3p is decreased in whole blood and plasma from patients with idiopathic PAH (IPAH). miR-34a-3p expression from whole blood and plasma from 2 cohorts was normalized to U6 and miR- 
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Downregulation of miR-34a-3p Mediates MiD49 and MiD51 Upregulation in PAH
A comparison of miRNA expression profiles in PASMCs from patients with PAH and healthy controls ( Figure 4A ) identified 25 miRNAs that were significantly downregulated in PAH (Table II in the online-only Data Supplement). In silico analysis of these miRNAs identified potential miR-34a-3p target sites within the 3′-UTR of MiD49 and MiD51 ( Figure 4B ). Decreased expression of miR-34a-3p in PAH PASMCs was confirmed by quantitative reverse transcription-polymerase chain reaction ( Figure 4C ). Binding of miR-34a-3p to the 3′-UTR of MiD49 and MiD51 was confirmed with a luciferase reporter fused to the 3′-UTR of the MiD49 or MiD51 gene ( Figure 4D ). Cotransfection of HEK293A cells with miR34a-3p mimic and the reporter constructs decreased luciferase activity, confirming binding of the miR to the 3′-UTR of MiD49 or MiD51. Downregulation of miR34a-3p was also found in the whole blood of monocrotaline and Su/Hx PAH rats ( Figure XA in the online-only Data Supplement). Two temporally and geographically discrete cohorts of different ethnicities showed a significant decrease in miR-34a-3p expression in whole blood and plasma from patients with idiopathic PAH compared with the age-and sex-matched healthy volunteers (Figure 4E and Table II in the online-only Data Supplement). The downregulation of plasma miR-34a-3p identified patients with PAH ( Figure 4F ) but did not predict disease-related mortality (data not shown). Similar findings were noted in the blood of both preclinical PAH models ( Figure XA in the online-only Data Supplement). Moreover, miR-34a-3p transfection decreased the expression of MiD49 and MiD51 in human PAH PASMCs ( Figure 5A ). Conversely, administration of anti-miR-34a-3p increased the expression of MiD49 and MiD51 in both normal human and rat PASMCs ( Figure 5B and Figure XB in the online-only Data Supplement). Augmenting miR-34a-3p fused the mitochondrial network, inhibited proliferation, and induced apoptosis in human PAH PASMCs (Figure 5C-5H) . miR-34a-3p mimic transfection also decreased proliferation and mitochondrial fission in PASMCs from normal, monocrotaline PAH, and Su/Hx PAH rats ( Figure XC -XG in the online-only Data Supplement).
Therapeutic Implications of the miR-34a-3p-MiD Pathway In Vivo
The therapeutic efficacy of silencing MiDs or augmenting miR-34a-3p was determined by nebulizing rats early in the course of monocrotaline-induced PAH with siRNAs against either MiDs or an miR-34a-3p mimic. Treatment with either siMiD or the miR-34a-3p mimic, but not appropriate control materials, caused marked hemodynamic improvement, with decreased mean pulmonary artery pressure, right ventricular systolic pressure, and total pulmonary resistance, as well as increased cardiac output ( Figure 6A and 6B). These hemodynamic benefits were accompanied by regression of vascular obstruction, as quantified by a decrease in medial thickness in small pulmonary arteries of monocrotaline-treated rats ( Figure 6C and Figure 
DISCUSSION
This study has 5 novel findings: (1) MiDs cause fission, and this is increased in a human disease (PAH). (2) Inhibiting MiD expression prevents mitotic fission in health and disease. (3) MiD inhibition stops cell proliferation and increases apoptosis. (4) MiD expression is epigenetically upregulated by a decrease in miR-34a-3p, both in experimental PAH and in patients with PAH. (5) These discoveries were translated into 2 new therapies that attenuate PAH in a rodent model (nebulized siMiD49 or siMiD51 or nebulized miR-34a-3p).
This study clarifies the role of the Drp1 binding partners, MiD49 and MiD51, in normal cell biology while simultaneously highlighting the impact of their upregulation on the pathogenesis of PAH. In normal vascular cells, MiDs function as an important link between mitosis and mitochondrial fission. In PAH, the upregulation of MiD49 and MiD51 supports increased mitotic mitochondrial fission, leading to pathological mitochondrial fragmentation, cellular proliferation, and apoptosis resistance. We were able to use superresolution microcopy to image, for the first time, the macromolecular fission apparatus ( Figure 1B) . We demonstrated that it contained both Drp1 and MiDs. In PAH, there were qualitatively more MiDs at the site of fission, and the fission apparatus appeared denser, consistent with the notion that increased MiDs focus the constriction apparatus, thereby enhancing fission. 12 Patients with PAH displayed individual variation in terms of which of the MiDs was elevated ( Figure 1A) , with patients often exhibiting increased MiD49 or MiD51, but not both, relative to control. This heterogeneity of expression was also seen at the mRNA level (data not shown). Despite this heterogeneity, patients with PAH displayed a conserved, fragmented mitochondrial phenotype regardless which of the MiDs was upregulated ( Figure 2A) . Overexpression of either MiD49 or MiD51 in isolation also was sufficient to reproduce the mitochondrial and proliferative phenotype of PAH in normal PASMCs ( Figure 2E , 2F, and 2H), highlighting a redundancy in the function of the 2 MiDs and suggesting that even healthy cells possess a sufficient basal pool of activated Drp1 to drive fission and proliferation 
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when MiD levels increase. Our findings are at odds with those of Palmer et al, 14 who suggested that MiD overexpression inhibited fission, possibly by sequestering inactivated Drp1. The basis for this difference is unclear; however, our findings are robust ( Figure 2E and 2F) .
This work advances the field from an earlier view that fission reflects primarily the expression, activity, or posttranslational modification of Drp1 (reviewed elsewhere 4 ). It is now clear the expression and function of the MiDs are critical determinants of mitochondrial dynamics and cell cycle regulation. This view is further supported by our observation that silencing MiDs is sufficient to restore mitochondrial fusion (Figure 2A-2D) , to slow cell proliferation ( Figure 2G ), and to enhance apoptosis ( Figure 2J ) in PAH PASMCs. In this regard, MiD49 and MiD51 are unique because silencing other Drp1 receptor proteins, mitochondrial fission factor or Fis1, did not alter cell proliferation or mitochondrial fission ( Figure VID -VIH in the online-only Data Supplement). MiDs appear to have a special role in the fission that accompanies mitosis, whereas Fis1 appears to be important in pathological fission, as occurs in ischemia/reperfusion injury. 26 Although MiDs regulate fission independently of other Drp1 binding partners ( Figure  VIA in the online-only Data Supplement), the inability of MiDs to promote fission in mouse embryonic fibroblasts lacking Drp1 ( Figure III in the online-only Data Supplement) demonstrates that the availability of activated Drp1 is essential to this process. This new work adds detail to our previous discovery that inhibiting mitotic fission slows cell cycle progression. We are now showing that Drp1 binds MiDs to mediate mitotic fission. Superresolution microscopy demonstrates the assembly of these partners at focal areas of fission as part of the macromolecular fission apparatus ( Figure 1B) . The Drp1-dependent proliferative effect of MiDs indicates that they are obligatory Drp1 binding partners in hyperproliferative disease. We did not study the effects of MiD expression on mitochondrial membrane potential.
Besides hyperproliferation and apoptosis resistance, PAH PASMCs exhibit another pseudoneoplastic phenotype by displaying perturbed oxygen sensing resulting from dysregulated mitochondrial redox signaling. This increases reliance on glycolysis, thereby creating the Warburg phenomenon. 2 We show that inhibiting MiDs increases apoptosis ( Figure 2J ) and restores oxidative metabolism and mitochondrial calcium uniporter expression ( Figure VIIB and VIIC in the online-only Data Supplement), consistent with our recent discovery that the downregulation of mitochondrial calcium uniporter is a central contributor to both Warburg metabolism and fission in PAH 19 ( Figure VIIB in the online-only Data Supplement). This indicates that the miR-34a-3p-MiDDrp1 pathway interacts with the miR-25-and miR-138-mitochondrial calcium uniporter pathway. We also identified the mechanisms by which MiDs regulate fission and cell cycle progression ( Figure 7A ). MiDs are Drp1 binding partners and attract more Drp1 to the outer mitochondrial membrane. 12 Thus, greater MiD expression is expected to enhance fission, as we observed ( Figure 2E and 2F) . However, we show that MiDs also regulate kinases that control Drp1 activity. Drp1 phosphorylation can be initiated by several kinases, including CDK1 and ERK, 10, 23, 24 which activate Drp1 through phosphorylation of serine 616. 3, 27 We found that silencing MiDs inhibited ERK1/2 ( Figure 3B ) and decreased phosphorylation of Drp1 at serine 616 ( Figure 3A) , supporting the dual mechanisms of MiD-induced fission. However, silencing MiDs did not increase the expression of the mitochondrial fusion mediators Mfn1, Mfn2, and OPA1. Indeed, siMiD51 decreased the expression of Mfn1 and OPA1 ( Figure IVA -IVC in the online-only Data Supplement). Thus, siMiD-mediated mitochondrial fusion does not result from upregulation of fusion mediators.
Knocking down MiDs caused cell cycle arrest at the G1/G0 phase ( Figure 2I ). Progression of cell cycle in the early G1 phase versus the transition from G1 to GS phase is mediated by CDK4 versus CDK2, respectively. 28 The activation of CDK2 involves dephosphorylation of Tyr15 and Thr14. 29 Our results revealed that silencing MiDs does not inhibit CDK2 activity, as evidenced by the unchanged phosphorylation status at Tyr15 of CDK2 ( Figure IXG in the online-only Data Supplement). However, knocking down MiDs inhibited CDK4 activity by downregulating CDK4 expression and phosphorylation at threonine 172 30 ( Figure 3D and Figure IXD and IXE in the online-only Data Supplement). Silencing MiDs also increased the expression of the CDK4 inhibitors p21 Waf131 and p27 Kip132 ( Figure 3E and 3F and Figure IXF in the online-only Data Supplement). Our observation is supported by studies showing that ERK is a negative regulator of p27 Kip1 . 33, 34 Therefore, siMiD-mediated inhibition of cell cycle arrest can be explained by the inhibition of ERK1/2 activity achieved by silencing MiDs, which in turn activates p27 Kip1 , resulting in decreased CDK4 activity. Taken together, these results show a multifactorial mechanism underlying the inhibition of mitochondrial fission and cell cycle arrest at the G1 phase achieved by silencing MiDs (Figures 2A-2D, 2I , and 7A). We previously showed that inhibiting Drp1 or augmenting Mfn2, both resulting in impaired mitotic fission, also results in cell cycle arrest. 10 In addition to these effects on cell cycle kinases, silencing MiDs downregulated PDGF receptors α and Figure 6 Continued. ****P<0.0001, 1-way ANOVA; n=4-10 per group). C, Representative images of longitudinal and cross sections of small pulmonary arteries and summary data indicating that the regression of PAH caused by siMiD49 or siMiD51 or by miR-34a-3p mimic was associated with a decrease in the wall thickness in MCT PAH rats. Regression of PAH was assessed by measuring the percent of wall thickness by immunofluorescence staining of smooth muscle actin (SMA) and von Willebrand Factor (vWF) (blue, 4', 6-diamidino-2-phenylindole [DAPI]; red, SMA; green, vWF) (***P<0.001, 1-way ANOVA; n=4-5 per group). Figure 3C ). PDGF is a potent mitogen that triggers cell proliferation, migration, transformation, and survival, [35] [36] [37] all processes relevant to the pathogenesis of PAH. Indeed, PDGF receptors are activated in PAH, 38 and inhibitors of PDGF receptor such as imatinib have demonstrated therapeutic benefit in animal models and in some patients. 38, 39 PDGF binding to the PDGF receptors activates the mitogen-activated protein kinase signal transduction cascade, resulting in the phosphorylation and activation of ERK1/2. Activated ERK1/2 then trans- Figure 7 . Demonstration of the therapeutic relevance of the microRNA (miR)-34a-3p-mitochondrial dynamics protein (MiD) pathway in a preclinical model. A, Representation of the proposed miR-MiD pathway in pulmonary arterial hypertension (PAH) relative to normal. B, Decreased expression of miR-34a-3p in patients with PAH leads to increased expression of the dynamin-related protein 1 (Drp1) binding partners MiD49 and MiD51, which in turn increases mitotic fission and promotes cell proliferation. CDK4 indicates cyclin-dependent kinase 4; ERK, extracellular signal-regulated kinase; OMM, outer mitochondrial membrane; p-, phospho-; PDGF, platelet-derived growth factor; and SR, sarcoplasmic reticulum.
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locates to the nucleus and enhances the expression of transcription factors related to cell proliferation. 40 It is likely that siMiD-induced downregulation of PDGF receptors contributes to the observed inhibition of cell proliferation via the mitogen-activated protein kinase signaling pathway, as evidenced by the inhibition of 2 members of the mitogen-activated protein kinase signaling pathway, Raf-1 and ERK1/2 ( Figure 3B and 3C and Figure IXB and IXC in the online-only Data Supplement; see proposed pathway schematic in Figure 7A) . Although an interaction between MiDs and PDGF receptors remains speculative, it is important to note that MiDs are located on the outer mitochondrial membrane and that they possess free cytosolic domains responsible for Drp1 binding. 13, 14 Furthermore, mitochondria are highly motile, dynamic organelles. Indeed, the outer mitochondrial membrane protein Mfn2 interacts with Ras, which is also located on the cell membrane, just like PDGF receptors. 41, 42 Therefore, it is not unlikely that MiDs may directly interact with PDGF receptors.
The present study identifies depressed miR-34a-3p expression as the primary driver of pathological MiD upregulation in PAH. In general, upregulation of an miR suppresses its target species, whereas downregulation of the miR, as in the case of miR-34a-3p in PAH PASMCs, would be expected to permit increase expression of its targets (MiD49 and MiD51). The ability to increase ( Figure 5B and Figure XB in the online-only Data Supplement) or decrease ( Figure 5A ) MiDs through manipulation of miR-34a-3p confirms the central role that this miR plays in the mitochondrial fission phenotype of PAH. Further certainty of the predicted role of miR-34a-3p in regulating MiDs comes from our direct experimental confirmation that the miR indeed binds the 3′-UTR of both MiD49 and MiD51 ( Figure 4D ).
Although the role of miR-34a-3p is not well established in human disease, its complementary strand, miR-34a-5p, has been implicated in many human cancers [43] [44] [45] and in PAH, where its suppression has been linked to the PDGF receptor α-mediated hyperproliferation of human PASMCs 46 and vascular remodeling in response to chronic hypoxia. 47 Additional reports have shown that miR-34-3p is coexpressed with its complementary 5p strand in cancer cells; however, it targets different groups of transcripts. 48 The downregulation of miR-34a-3p expression in PAH may relate to the hypermethylation of the 5'-C-phosphate-G-3 (CpG) island in the promoter region of the MIR34A gene. This is supported by the studies with several cancers that displayed CpG methylation of the promoter of the precursor MIR34A and subsequent loss of miR-34a-5p expression. 49, 50 Here, we demonstrate a consistent downregulation of miR-34a-3p in 3 PAH patient cohorts and 2 rodent models of PAH ( Figure XA in the online-only Data Supplement). Decreased miR-34a-3p expression was observed in PASMCs from Canadian subjects ( Figure 4C ) and in the whole blood and plasma collected from UK and China cohorts ( Figure 4E ). Because circulating levels of miR-34-3p are depressed in patients with PAH, which correlates with expression in the PASMC itself, this miR also has potential as a diagnostic test for PAH. The expression of circulatory miR-34a-3p predicted the presence of PAH but did not predict clinical outcomes ( Figure 4F ), suggesting that larger sample sizes may be required to confirm the usefulness of this miR as a biomarker for PAH.
Our in vitro data demonstrate that inhibition of MiDs causes a sustained state of mitochondrial fusion (Figure 2A-2D) , which decreases PASMC proliferation ( Figure 2G and Figures V and VIIIE-VIIIG in the online-only Data Supplement) and promotes apoptosis ( Figure 2J ). These findings provide the biological plausibility for the therapeutic targeting of MiDs or augmenting miR-34a-3p in PAH. We confirmed these therapeutic benefits by nebulizing siMiDs and miR-34a-3p in vivo and demonstrating the ability of these approaches to regress experimental PAH and to reduce cell proliferation in vivo ( Figure 6A-6C ). These findings are consistent with our previous observations that creating a state of sustained mitochondrial fusion, whether by inhibiting Drp1 3 or augmenting the fusion mediator mitofusin-2, 22 arrests cell proliferation and regresses PAH.
Limitations
There are few reports of the function or localization of MiD49 and MiD51. It has been reported that both MiDs are located exclusively at the outer mitochondrial membrane. 51 That study relied on heterologous overexpression of MiDs. However, we noted that MiDs are also expressed in the cytosol. This is consistent with a prior report that noted that although MiD51 was predominantly a mitochondrial protein, it also existed in the cytosol. 13 Extramitochondrial MiD may reflect the balance between levels of MiD and activated Drp1 or the existence of a splice variant/isoform of MiD that targets the MiD to an extramitochondrial location. Perhaps, like Drp1 itself, the MiDs may be involved in the division of other organelles such as lysosomes. These questions merit future study.
CONCLUSIONS
Excessive mitochondrial fission, which results in mitochondrial fragmentation, is a new hallmark of proliferative diseases, including PAH and cancer. 3, 10 We have shown that expression of the Drp1 binding partners MiD49 and MiD51 are increased in PAH and that this ORIGINAL RESEARCH ARTICLE increase drives pathological mitochondrial fission, cell proliferation, and apoptosis resistance. To the best of our knowledge, this is the first description of a role for dysregulated expression of MiD49 and MiD51 in human disease and clarifies the role of these Drp1 binding partners in normal cell biology. We also report increased MiD49 and MiD51 expression in the endothelium of diseased pulmonary arteries, as well as in BOECs isolated from patients with PAH ( Figure 1C and Figure IB in the online-only Data Supplement). Although the role of MiDs in the endothelium was not examined in detail in the present study, the mitochondria in PAH BOECs are also fragmented ( Figure  ID and IE in the online-only Data Supplement), indicating that similar mechanisms may be driving altered cellular proliferation and apoptosis resistance in this compartment of the vascular wall. Our work identifies decreased expression of miR-34a-3p as the cause of upregulated MiD49 and MiD51 in human PAH and highlights the potential value of this miR as a novel biomarker. Together, these studies identify the miR34a-3p-MiD-Drp1 axis as an important driver of the mitochondrial and cellular phenotype of PAH and a new target for therapeutic intervention. A schematic representation of the proposed role of miR-34a-3p in regulating MiD49 and MiD51 in PAH is provided in Figure 7B .
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